Efficacy and safety of etoricoxib in the treatment of osteoarthritis

References

• American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis. Update. Arthritis Rheum.46, 328–346 (2002).
   PubMed Web of Science ®Google Scholar
• Lawrence R, Helmick CG, Arnett FC et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum.41, 778–799 (1998).
   PubMed Web of Science ®Google Scholar
• Buckwalter J, Saltzman C, Brown T. The impact of osteoarthritis: implications for research. Clin. Orthop. Relat. Res.427(Suppl.), S6–S15 (2004).
   PubMed Web of Science ®Google Scholar
• Schnitzer T. Update of ACR guidelines for osteoarthritis: role of the coxibs. J. Pain Symptom Manage.23, S24–S30 (2002).
   PubMed Web of Science ®Google Scholar
• Cryer B, Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am. J. Med.104, 413–421 (1998).
   PubMed Web of Science ®Google Scholar
• Hochberg M. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist’s perspective. Clin. Exp. Rheumatol.19(6 Suppl. 25), S15–S22 (2001).
   PubMedGoogle Scholar
• Cannon C, Curtis SP, FitzGerald GA et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet368, 1771–1781 (2006).
   PubMed Web of Science ®Google Scholar
• Baraf H, Fuentealba C, Greenwald M et al. Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of the Etoricoxib versus Diclofenac sodium Gastrointestinal tolerability and Effectiveness (EDGE) trial. J. Rheumatol.34, 408–420 (2007).
   PubMed Web of Science ®Google Scholar
• Laine L, Curtis SP, Cryer B et al. for the MEDAL Steering Committee. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet369, 465–473 (2006).
   Web of Science ®Google Scholar
• Schnitzer T, Burmester GR, Mysler E et al. on behalf of the TARGET Study Group. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet364, 665–674 (2004).
   PubMed Web of Science ®Google Scholar
• Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N. Engl. J. Med.343, 1520–1528 (2000).
   PubMed Web of Science ®Google Scholar
• Agrawal N, Porras AG, Matthews CZ et al. Single and multi-dose pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, in man. J. Clin. Pharm.43, 268–276 (2003).
   PubMed Web of Science ®Google Scholar
• Agrawal N, Porras AG, Matthews CZ et al. Dose proportionality of oral etoricoxib, a highly selective cyclooxygenase-2 inhibor, in healthy volunteers. J. Clin. Pharm.41, 1106–1110 (2001).
   PubMed Web of Science ®Google Scholar
• Brater DC, Harris C, Redfern JS, Gertz BJ. Renal effects of COX-2 selective inhibitors. Am. J. Nephrol.21, 1–15 (2001).
   PubMed Web of Science ®Google Scholar
• Agrawal N, Rose MJ, Matthews CZ et al. Pharmacokinetics of etoricoxib in patients with hepatic impairment. J. Clin. Pharm.43, 1136–1148 (2003).
   PubMed Web of Science ®Google Scholar
• Rodrigues A, Halpin RA, Geer LA et al. Absorption, metabolism, and excretion of etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, in healthy male volunteers. Drug Metabol. Disp.31, 224–232 (2003).
   PubMed Web of Science ®Google Scholar
• Matsumoto A, Cavanaugh PF. Etoricoxib. Drugs of Today40, 395–414 (2004).
   PubMed Web of Science ®Google Scholar
• Cochrane D, Jarvis B, Keating GM. Etoricoxib. Drugs62, 2637–2651 (2002).
   PubMed Web of Science ®Google Scholar
• Dallob A, Hawkey CJ, Greenberg H et al. Characterization of etoricoxib, a novel, selective COX-2 inhibitor. J. Clin. Rheumatol.43, 573–585 (2003).
   Google Scholar
• Jordan K, Arden NK, Doherty M et al. EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann. Rheum. Dis.62, 1145–1155 (2003).
   PubMed Web of Science ®Google Scholar
• Hochberg M. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis. Semin. Arthritis Rheum.32(3 Suppl. 1), 4–14 (2002).
   PubMed Web of Science ®Google Scholar
• Sikes D, Agrawal NM, Zhao WW, Kent JD, Recker DP, Verburg KM. Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis. Eur. J. Gastroenterol. Hepatol.14, 1101–1111 (2002).
   PubMed Web of Science ®Google Scholar
• Pavelka K, Recker DP, Verburg KM. Valdecoxib is as effective as diclofenac in the management of rheumatoid arthritis with a lower incidence of gastroduodenal ulcers, results of a 26 week trial. Rheumatology42, 1207–1215 (2003).
   PubMed Web of Science ®Google Scholar
• Singh G, Fort JG, Goldstein JL et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I study. Am. J. Med.119, 255–266 (2006).
   PubMed Web of Science ®Google Scholar
• Hunt R, Harper S, Watson DJ et al. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events. Am. J. Gastroenterol.98, 1725–1733 (2003).
   PubMed Web of Science ®Google Scholar
• Wong J, Ramey DR, Singh G. Long-term morbidity, mortality, and economics of rheumatoid arthritis. Arthritis Rheum.44, 2746–2749 (2001).
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control. Prevalence of self-reported arthritis or chronic joint symptoms among adults. United States, 2001. Morbid. Mortal. Wkly Rep.51, 948–950 (2002).
   PubMedGoogle Scholar
• Gabriel S, Crowson CS, Luthra HS, Wagner JL, O’Fallon WM. Modeling the lifetime costs of rheumatoid arthritis. J. Rheumatol.26, 1269–1274 (1999).
   PubMed Web of Science ®Google Scholar
• Brune K, Hinz B. Selective cyclooxygenase-2 inhibitors: similarities and differences. Scand. J. Rheumatol.33, 1–6 (2004).
   PubMed Web of Science ®Google Scholar
• Schnitzer T, Hochberg MC. COX-2-selective inhibitors in the treatment of arthritis. Cleve. Clin. J. Med.69(Suppl. 1), S120–S130 (2002).
   Google Scholar
• Moore R, Derry S, Phillips CJ, McQuay HJ. Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice.BMC Musckuloskelet. Disord.7, 79 (2006).
   PubMed Web of Science ®Google Scholar
• Bresalier R, Sandler RS, Quan H et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med.352, 1092–1102 (2005).
   PubMed Web of Science ®Google Scholar
• Solomon S, McMurray JVJ, Pfeffer MA et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N. Engl. J. Med.352, 1071–1080 (2005).
   PubMed Web of Science ®Google Scholar
• Gottesdiener K, Schnitzer T, Fisher C et al. Results of a randomized, dose ranging trial of etoricoxib in patients with osteoarthritis. Rheumatology41, 1052–1061 (2002).
   PubMed Web of Science ®Google Scholar
• Fisher C, Bockow B, Curtis SP et al. Results of a 190-week randomized study demonstrated similar efficacy of etoricoxib compared with diclofenac in patients with OA. Ann. Rheum. Dis.62(Suppl. 1), 256 (2003).
   Google Scholar
• Fisher C, Curtis SP, Resnick H et al. Treatment with etoricoxib, a COX-2 selective inhibitor, resulted in clinical improvement in knee and hip osteoarthritis (OA) over 52 weeks. Arthritis Rheum.44(Suppl. 9), S135 (2001).
   Google Scholar
• Leung A, Malmstrom K, Gallacher AE et al. Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: a randomized double-blind placebo and active-comparator controlled 12-week efficacy trial. Curr. Med. Res. Opin18, 49–58 (2002).
   PubMed Web of Science ®Google Scholar
• Reginster J, Malmstrom K, Mehta A et al. Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomized studies of osteoarthritis patients. Ann. Rheum. Dis.66, 945–951 (2007).
   PubMed Web of Science ®Google Scholar
• Hunsche GO, Kong SX, Watson DJ. Impact of etoricoxib, a novel COX-2 inhibitor, on social and emotional quality of life in patients with osteoarthritis. Osteoporosis Intl13(Suppl. 3), 20 (2002).
   Web of Science ®Google Scholar
• Hunsche GO, Kong SX, Watson DJ. Improvement of physical functioning in patients with osteoarthritis treated with etoricoxib, naproxen, and placebo: results from two double-blind, randomized clinical trials. Ann. Rheum. Dis.61(Suppl. 1), 112 (2002).
   Google Scholar
• Matsumoto A, Melian A, Mandel DR et al. A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. J. Rheumatol.29, 1623–1630 (2002).
   PubMed Web of Science ®Google Scholar
• Zacher J, Feldman D, Gerli R et al. A comparison of the therapeutic efficacy and tolerability of etoricoxib and diclofenac in patients with osteoarthritis. Curr. Med. Res. Opin19, 725–736 (2003).
   PubMed Web of Science ®Google Scholar
• Bingham CR, Sebba AI, Rubin BR et al. Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies. Rheumatology46, 496–507 (2007).
   PubMed Web of Science ®Google Scholar
• Curtis S, Ko AT, Bolognese JA, Cavanaugh PF Jr, Reicin AS. Pooled analysis of thrombotic cardiovascular events in clinical trials of the COX.2 selective inhibitor etoricoxib. Curr. Med. Res. Opin22, 2365–2374 (2006).
   PubMed Web of Science ®Google Scholar
• Psaty B, Weiss NS. NSAID trials and the choice of comparators – questions of public health importance. N. Engl. J. Med.356, 328–330 (2007).
   PubMed Web of Science ®Google Scholar
• Geis GS. CLASS clarification: reaffirms the medicalimportance of the analyses and results. BMJ327, 143–144 (2003).
   PubMedGoogle Scholar
• Langman M, Kahler KH, Kong SX et al. Drug switching patterns among patients taking non-steroidal anti-inflammatory drugs: a retrospective cohort study of a general practitioners database in the United Kingdom. Pharmacoepidemiol. Drug Saf.10, 517–524 (2001).
   PubMed Web of Science ®Google Scholar
• Watson D, Bolognese JA, Yu C, Krupa D, Curtis S. Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDS. Curr. Med. Res. Opin.20, 1899–1908 (2004).
   PubMed Web of Science ®Google Scholar
• Scheiman J. Unmet needs in non-steroidal anti-inflammtory drug-induced upper gastrointestinal diseases. Drugs66(Suppl. 1), 15–21 (2006).
   PubMedGoogle Scholar
• De Smet B, Fendrick AM, Stevenson JG, Bernstein SJ. Over and under-utilization of cyclooxygenase-2 selective inhibitors by primary care physicians and specialists: the tortoise and the hare revisited. J. Gen. Intern. Med.21, 694–697 (2006).
   PubMed Web of Science ®Google Scholar
• Sturkenboom M, Burke TA, Dieleman JP, Tangelder MJD, Lee F, Goldstein JL. Underutilization of preventive strategies in patients receiving NSAIDs. Rheumatol.42(Suppl. 3), iii23–iii31 (2003).
   PubMed Web of Science ®Google Scholar
• Lanas A, Ferrandez A. Inappropriate prevention of NSAID-induced gastrointestinal events among long-term users in the elderly. Drugs Aging24, 121–131 (2007).
   PubMed Web of Science ®Google Scholar
• Ramey D, Watson DJ, Yu C, Bolognese JA, Curtis SP, Reicin AS. The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDS: an updated combined analysis. Curr. Med. Res. Opin.21, 715–722 (2005).
   PubMed Web of Science ®Google Scholar
• Rawson NSB, Nourjah P, Grosser SC, Graham DJ. Factors associated with celecoxib and rofecoxib utilization Ann. Pharmacother.39, 597–602 (2005).
   PubMed Web of Science ®Google Scholar
• Catella-Lawson F, Reilly MP, Kapoor SC et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N. Engl. J. Med.345, 1809–1817 (2001).
   PubMed Web of Science ®Google Scholar
• Reilly I, FitzGerald GA. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood69, 180–186 (1987).
   PubMed Web of Science ®Google Scholar
• Nussmeier N, Whelton AA, Brown MT et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N. Engl. J. Med.352, 1081–1091 (2005).
   PubMed Web of Science ®Google Scholar
• Jick S, Kaye JA, Russmann S, Jick H. Nonsteroidal antiinflammatory drugs and acute myocardial infarction in patients with no major risk factors. Pharmacotherapy26, 1379–1387 (2006).
   PubMed Web of Science ®Google Scholar
• Jick S, Kaye JA, Jick H. Diclofenac and acute myocardial infarction in patients with no major risk factors. Br. J. Clin. Pharmacol.64(5), 662–627 (2007).
   PubMed Web of Science ®Google Scholar
• Hernandez-Diaz S, Vara-Lorenzo C, Garcia-Rodriguez LA. Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction. Basic Clin. Pharmacol. Toxicol.98, 266–274 (2006).
   PubMed Web of Science ®Google Scholar
• Schneeweiss S, Solomon DH, Wang PS, Rassen J, Brookhart MA. Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis. Arthritis Rheum.54, 3390–3398 (2006).
   PubMed Web of Science ®Google Scholar
• Kearney P, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. Brit. Med. J.332, 1302–1308 (2007).
   Google Scholar
• Solomon D, Avorn J, Sturmer T, Glynn RJ, Mogun H, Schneeweiss S. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk. Arthritis Rheum.54, 1378–1389 (2006).
   PubMed Web of Science ®Google Scholar
• McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase. A systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA296, 1633–1644 (2006).
   PubMed Web of Science ®Google Scholar
• Scheiman J, Fendrick AM. Summing the risk of NSAID therapy. Lancet7369, 1580–1581 (2007).
   Google Scholar
• Scheiman JM, Fendrick AM. Practical approaches to minimizing gastrointestinal cardiovascular safety concerns with COX-2 inhibitors and NSAIDS. Arthritis Res. Ther.7(Suppl. 4), S23–S29 (2005).
   PubMed Web of Science ®Google Scholar